TOP - August 2018, Vol 11, No 2

A new study presented at the 2018 American Association for Cancer Research meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment.

“It is time for us to bury the concept of maximum-tolerated dose in the world of targeted therapy,” according to Allen S. Lichter, MD, FASCO.

While the industry does its part to improve the quality and completeness of applications, the FDA is taking action to enhance the efficiency of its review process.

Patients with indolent subtypes of NHL have a relatively good prognosis with a median survival as long as 20 years, although these subtypes of the disease are typically not curable in advanced stages.

Page 2 of 2
Results 11 - 14 of 14